ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

FDA Adopts Final Diagnostics X-Ray Rule Amendment

September 9, 1977

Ethics Commission Backs Limited Pilot Program for Compensation Of Injured Research Subjects

January 16, 1981

In Brief: Kennedy, Waxman May Agree On Simple Extension Of Biomedical Research Authority, Including NCI

November 21, 1980

Funding For Groups, Working With Industry, Still Unresolved

June 12, 1998

Lawrence Corey Named President Of Fred Hutchinson Cancer Research Center

August 6, 2010

NCI News Roundup: clinical Trials Initiatives Explained in Lectures Available Online

June 11, 1999